Antischistosomal action of thioxo-imidazolidine compounds: An ultrastructural and cytotoxicity study  by Neves, Juliana Kelle A.L. et al.
Experimental Parasitology 128 (2011) 82–90Contents lists available at ScienceDirect
Experimental Parasitology
journal homepage: www.elsevier .com/locate /yexprAntischistosomal action of thioxo-imidazolidine compounds: An ultrastructural
and cytotoxicity study
Juliana Kelle A.L. Neves a,⇑, Maria do Carmo Alves de Lima a, Valéria Rego Alves Pereira b,
Cristiane Moutinho Lagos de Melo b, Christina Alves Peixoto c, Ivan da Rocha Pitta a,
Mônica Camelo Pessoa Azevedo Albuquerque d, Suely Lins Galdino a
a Laboratório de Planejamento e Síntese de Fármacos (LPSF), Departamento de Antibióticos, Centro de Ciências Biológicas, Universidade Federal de Pernambuco (UFPE),
Av. Prof. Moraes Rego s/n, Cidade Universitária, 50670-901 Recife, PE, Brazil
b Laboratório de Imunogenética, Departamento de Imunologia, Centro de pesquisas Aggeu Magalhães, Fundação Oswaldo Cruz (FIOCRUZ), 50670-420 Recife, PE, Brazil
c Laboratório de Ultraestrutura, Departamento de Entomologia, Centro de Pesquisas Aggeu Magalhães, Fundação Oswaldo Cruz (FIOCRUZ), 50670-420 Recife, PE, Brazil
d Laboratório de Imunopatologia Keizo Asami (LIKA), Universidade Federal de Pernambuco, Av. Prof. Moraes Rego s/n, Cidade Universitária, 50670-901 Recife, PE, Brazil
a r t i c l e i n f oArticle history:
Received 15 November 2010
Received in revised form 19 January 2011
Accepted 25 January 2011
Available online 16 February 2011
Keywords:
Schistosomiasis
Schistosoma mansoni
Praziquantel
Imidazolidinone derivatives
in vitro0014-4894 2011 Elsevier Inc.
doi:10.1016/j.exppara.2011.01.021
⇑ Corresponding author. Address: Departamento
Ciências Biológicas, Universidade Federal de Pernam
s/n, Cidade Universitária, 50670-901 Recife, PE, Brazi
E-mail address: lemoineju@gmail.com (J.K.A.L. Nev
Open access under the Elsa b s t r a c t
Schistosomiasis is a disease caused by helminthes of the genus Schistosoma, which threatens approxi-
mately 207 million people worldwide. Recently, strains of Schistosoma mansoni appear to be developing
tolerance and resistance against Praziquantel, the most commonly available drug on the market used in
the treatment of disease. This worrisome development justiﬁes studies that seek alternatives for the pre-
vention, treatment and cure of this disease. This study aimed to evaluate the in vitro activity of new imi-
dazolidine compounds 1-benzyl-4-[(4-chloro-phenyl)-hydrazono]-5-thioxo-imidazolidin-2-one (LPSF/
PT-5) and 1-(4-chloro-benzyl)-4-[(4-ﬂuoro-phenyl)-hydrazono]-5-thioxo-imidazolidin-2-one (LPSF/PT-
11) against adult worms of S. mansoni. LPSF/PT-5 and LPSF/PT-11 imidazolidine derivatives showed rel-
evant schistosomicidal activity in vitro and induced signiﬁcant ultrastructural alterations in worms and
cell death: results similar to praziquantel. Thus, it is possible that these imidazolidine derivatives can
be future candidates as schistosomotic drugs, but further studies are needed to elucidate the induced
mechanisms behind this response.
 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Schistosomiasis mansoni infection, an endemic disease of world-
wide importance in terms of public health, affects large geograph-
ical areas in several countries. This tropical disease affects
approximately 207 million people worldwide and is responsible
for almost 500,000 deaths each year (Chitsulo et al., 2004; Gryseels
et al., 2006). In Brazil, there are 8–10 million people infected and
about 30 million at risk of infection (WHO, 1993). Praziquantel
(PZQ) remains the standard drug for the treatment of schistosomi-
asis worldwide. PZQ is effective against all Schistosoma species
infecting humans and has been extensively tested. But, this drug
is ineffective against immature forms and now there are reports
of resistance in some strains, which has worried the world’s public
health organizations (Ismail et al., 1999; Pica-Mattoccia and Cioli,
2004). Imidazolidines are a broad class of bioactive pentagonalde Antibióticos, Centro de
buco, Av. Prof. Moraes Rego
l. Fax: +55 81 2126 8346.
es).
evier OA license.heterocyclic compounds with diverse biological activity (Rossi
and Zelnik, 2000). Imidazolidines have antifungal, antimicrobial,
anti-Trypanosoma cruzi and schistosomicidal properties (Caterina
et al., 2008). The schistosomicidal properties of imidazolidine
derivatives have been demonstrated by in vitro studies with adult
S. mansoni worms (Oliveira et al., 2004; Albuquerque et al., 2005;
Pitta et al., 2005). In addition, recently, we published a study that
also demonstrated the efﬁcacy of two new imidazolidine deriva-
tives, named RZS 2 and RZS 5 (Neves et al., 2010). Here, we also
investigated two imidazolidine compounds against adult worms
of S. mansoni. The 1-benzyl-4-[(4-chloro-phenyl)-hydrazono]-5-
thioxo-imidazolidin-2-one, encoded LPSF-PT-05 (CAS Registry
Number 197504-87-3) (Brandão et al., 1997; Pitta et al., 2005, 2006)
and the new compound 1-(4-chloro-benzyl)-4-[(4-ﬂuoro-phenyl)-
hydrazono]-5-thioxo-imidazolidin-2-one, encoded LPSF-PT-11
were synthesized by the Laboratório de Planejamento e Síntese
de Fármacos-LPSF (UFPE) using diazonium ions formed from a phen-
ylamine that acts as an electrophylic reagent and engages with the
active hydrogen in position 5 of benzyl-thioxo-imidazolidinones,
yielding the arylazo imidazolidine LPSF-PT-5 and LPSF-PT-11. Our
aim was analyze the anti-S. mansoni activity and investigate the
possible cytotoxicity induced, in vitro, by these new compounds
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test and ultrastructural investigation.2. Materials and methods
2.1. LPSF/PT-11 1-(4-chloro-benzyl)-4-[(4-ﬂuoro-phenyl)-hydrazono]-
5-thioxo-imidazolidin-2-one (LPSF/PT-11) preparation method and
Praziquantel obtention
In a 100 mL ﬂask, at a temperature of 0 C was added 4-ﬂuoro-
aniline (0.138 g 1.24 mmol) in presence of 14 mL 50% HCl and 0.3 g
sodium nitrite dissolved in 6 mL of water. After a stirring of 10 min
was added slowly 3-(4-chloro-benzyl)-4-thioxo-imidazolidin-2-
one (0.298 g 1.24 mmol) dissolved in 15 mL of an aqueous solution
of NaOH 5%. Then let the mixture under stirring at 0 C for 3 h. The
reaction was monitored by TLC. The precipitated formed was
recrystallized from an ethanol–water mixture. The melting point
was measured in a capillary tube on a Quimis apparatus. Thin layer
chromatography was performed on silica gel plates (Merck
60F254). Infrared spectra of 1% KBr pellets were recorded on a Bruker
IFS66 spectrometer. 1H NMR spectra were recorded on a Bruker
AC 300 P spectrophotometer in DMSO-d6 as the solvent, with
tetramethylsilane as the internal standard. Mass spectra were
recorded on an Mass spectra were recorded on a DelsieNermag
R1010 C spectrometer on the EI. C16H12ClFN4OS Yield 65%; M.p.
225 C decomposition; Rf (CH2Cl2:CH3OH 9:1) 0.63; IR (KBr;
m cm1) 2920, 1590, 1493, 1356, 1220 cm1; 1H NMR (DMSOd6 d
ppm) 4.98 (s, 2H, CH2), 7.38 (s, 1H, CH ethylenic), 7.16–7.29 (m,
4H, phenyl), 7.33 (d, 2H, o benzyl, J = 9 Hz), 7.40 (d, 2H, m benzyl,
J = 9 Hz), 11.58 (s, NH, hydrazono), 13.37 (s, NH, imidazolidinic);
MS m/z (%)M+. 362 (3.428), M + 2 364 (2.541), 159(23.6),
128(36.8), 125(100), 127(64.4).
The praziquantel was purchase from Sigma Chemical Co., (St.
Louis, MO, USA – lot. 044K1032).
2.2. Parasites obtention and intermediary and deﬁnitive hosts
The BH (BH - Belo Horizonte, MG, Brazil) strain cercariae of
S. mansoni that has been maintained at the Laboratório de Imuno-
patologia Keizo Asami-LIKA was used throughout this study. The
strain was kept after it had passed through Biomphalaria glabrata
mollusks provided by the Department of Tropical Medicine
(Universidade Federal de Pernambuco). As deﬁnitive host were used
Swiss mice females (n = 15), average weight 20 ± 2 g and 4 weeks of
age. These animals were obtained and maintained at the animal
facilities of the Laboratório de Imunologia Keizo Asami (LIKA) of
the Universidade Federal de Pernambuco, Recife, Brazil. The ani-
mals were infected by means of exposure to a S. mansoni cercaria
suspension containing approximately 100 cercaria, using the tail
immersion technique (Sayed et al., 2008). Animals were housed in
a controlled temperature and light environment, and were given
water and commercial chow ad libitum. The experiments were
approved by the Universidade Federal de Pernambuco Animal
Experiments Ethics Committee, Process No. 007639/2007-12, in
accordance with Law 9.605 Article 32 Decree 3179. Art 17.
2.3. Anti-S. mansoni and scanning electronic microscopy assays
Animals were submitted to perfusion 8 weeks post infection
and worms were collected by mesenteric and portal veins. For
anti-S. mansoni in vitro test, worms were maintained in a RPMI-
1640 medium (Sigma Chemical Co., St. Louis, MO) buffered to pH
7.5, supplemented with HEPES (20 mM), 10% fetal bovine serum,
penicillin (100 U/mL), and streptomycin (100 lg/mL). Incubation
was carried out at 37 C in a humid atmosphere containing 5%CO2 gas. LPSF/PT-5 and LPSF/PT-11 imidazolidine derivatives were
dissolved in 1.6% dimethyl sulphoxide (DMSO) and used in concen-
trations varying from 32 to 320 lM, which were added to the med-
ium containing the worms after a 2 h period of adaptation to the
culture medium. Duplicates were carried out for each concentra-
tion used. One pair of adult worms/well was used in this study.
The parasites were kept for 5 days and monitored every 24 h to
evaluate their general condition: motor activity, alterations in the
integument, mortality rate. In the PZQ group, the same methodol-
ogy was used, but the concentration ranged from 10 to 80 lM. The
control worms were treated only with DMSO in RPMI 1640 med-
ium. For microscopic assay, at 1, 3, 6 and 12 h after treatment with
100 lM (LPSF/PT-5 and LPSF/PT-11 imidazolidines) or 80 lM (PZQ)
the worms were ﬁxed in 2.5% glutaraldehyde in 0.1 M phosphate
buffer (pH 7.2) for 2 h at ambient temperature. Then, they were
washed twice in the same buffer and post-ﬁxed in 1% osmium
tetroxide in phosphate buffer for 1 h at ambient temperature. All
worms were dehydrated in ethanol, washed several times in
100% ethanol, critical-point-dried in CO2, mounted on stubs, coated
with gold, and examined under a JEOL 25SII scanning electron
microscope.
2.4. Animals used for cytotoxicity and cellular viability assays
Male BALB/c mice (6–8 weeks old/n = 10) were raised at the ani-
mal facilities of the Fundação Oswaldo Cruz (Rio de Janeiro, Brazil)
and maintained at the animal facilities of the Centro de Pesquisa
Aggeu Magalhães of the Fundação Oswaldo Cruz in Recife, Brazil.
All mice were sacriﬁced and their spleens were removed in accor-
dance with the Fundação Oswaldo Cruz Commission for Experi-
ments with Laboratory Animals (Ministry of Health, Brazil, 0266/
05).
2.5. Obtaining spleen cells
Spleen cells were obtained according to a previously established
protocol (Pereira et al., 2004). After killing the animal with CO2 gas,
the spleen of each mouse was removed aseptically and placed in a
Falcon tube containing RPMI 1640 with fetal calf serum (complete
medium). In a vertical ﬂow, each spleen was transferred to a Petri
dish where they were soaked. The cell suspensions obtained were
transferred to Falcon tubes containing approximately 10 mL of
incomplete medium, centrifuged at 4 C, 200g for 5 min. After dis-
carding the supernatant, distilled water was added to the sediment
to promote lysis of red blood cells. The supernatant, containing no
cellular debris was collected and centrifuged at 4 C, 200g for
5 min. The sediment (containing cells) was resuspended in com-
plete RPMI 1640. An aliquot of each cell suspension was separated,
diluted in trypan blue to be quantiﬁed in a Neubauer chamber and
cell viability was determined.
2.6. In vitro cytotoxicity assay
Cytotoxicity of the compounds was determined using BALB/c
mice splenocytes (6  105 cells well1) cultured in 96-well plates
in RPMI 1640 medium (Sigma Chemical Co., St. Louis, MO) supple-
mented with 10% fetal calf serum (FCS; Cultilab, Campinas, SP, Bra-
zil) and 50 lg/mL of gentamycin (Novafarma, Anápolis, GO, Brazil).
Each imidazolidine was evaluated in six concentrations (1, 5, 10,
25, 50 and 100 lg mL1), in triplicate in two independent assays
(experimental group). Cultures with only splenocytes and medium
were considered control group and Praziquantel was used as the
standard drug (positive control). Cultures were incubated in the
presence of 3H-thymidine (Amersham Biosciences) (1 lCi/well)
for 24 h at 37 C and 5% CO2. After this period, the content of the
plate was harvested to determine the 3H-thymidine ([3H]TdR)
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ard). This technique uses Tritiate Timidine that acts through the
incorporation of tritium into the DNA of cells and is the most com-
monly utilized technique today for cytotoxicity detection in im-
mune cells (Pechhold et al., 2002). The toxicity of the compounds
was determined by comparing the percentage of 3H-thymidine
incorporation (as an indicator of cell viability) of imidazolidine-
treated wells in relation to untreated wells. Non-cytotoxic concen-
trations were deﬁned as those causing a reduction of 3H-thymidine
incorporation below 30% in relation to untreated controls. In prazi-
quantel treatments six concentrations were also used (1, 5, 10, 25,
50 and 100 lg/mL).2.7. Analysis of cellular viability using annexin V-FITC and propidium
iodide staining
Immune spleen cells were treated with Praziquantel (PZQ) or
LPSF/PT-5 or LPSF/PT-11 at 1 lg/mL concentration, respectively.
These treated cells were maintained in culture in 24-well plates
(TPP) for 24, 48 and 72 h to analyze the cellular viability of these
cells after these 3 incubation times. Cells without treatment (con-
trol) were used as negative control. After this, lymphocytes were
centrifuged at 4 C, 450g for 10 min. After discarding the superna-
tant, 1 mL of PBS 1 was added to the sediment, which was then
centrifuged at 4 C, 450g for 10 min. After discarding the superna-
tant, the pellet was resuspended in a binding buffer (10 mM HEPES
(pH 7.4), 150 mM NaCl, 5 mM KCl, 1 mMMgCl2, and 1.8 mM CaCl2)
and annexin V conjugated with ﬂuorescein isothiocyanate (FITC)
(1:500) and propidium iodide (PI, 20 lg/mL; 106 cells) was added
in each labeled cytometer tube. Flow cytometry was performed
in a FACSCalibur (BD Biosciences) and analyzed using Cell Quest
Pro software (BD Biosciences). Results analysis was performed onFig. 1. (A–D) Images of S. mansoni adult male control at 1, 3, 6 and 12 h of incubation, res
1000) and (D, 3350) showing a large number of tubercles (t) with their spines.graphs by dot plot. Spleen cells in the late stage of apoptosis (An-
nexin-FITC+/PI+) were considered double positives, whereas only
PI+ cells were necrotic cells. Annexin-FITC+/PI- represented spleno-
cytes in the early stage of apoptosis. Viable cells were considered
double negatives.
2.8. Statistical analysis
Data were analyzed using non-parametric tests. To detect dif-
ferences between groups, the Mann–Whitney U test and Tukey t
test were used. All results were expressed by mean values of
groups ± standard deviation and were analyzed considering the
value of p < 0.05 as statistically signiﬁcant.
3. Results
3.1. LPSF/PT-5 and LPSF/PT-11 induced ultrastructural alterations in
worm teguments
Male worms treated only with DMSO in RPMI 1640 medium
were used as a negative control. In the control, the parasite tegu-
ment was observed with its tubercles and numerous spines, oral
and ventral suckers in normal state at 1, 3, 6 and 12 h of incuba-
tion, respectively (Fig. 1A–D). Parasites were exposed to 100 lM
of LPSF/PT-5 and LPSF/PT-11 or 80 lM of PZQ and were collected
at 1, 3, 6 and 12 h intervals for ultrastructural investigation. Seri-
ous damage induced by imidazolidines on worms was observed
and was similar to PZQ. With the derived LPSF/PT-5, after 1 h of
incubation, imidazolidine promoted blistering and peeling of the
tegument; after 3 h of contact there was an increasing number of
blisters between the tubercles and changes in the suckers; after
6 h of incubation, disruption of the blisters, spine loss and tissuepectively (A, 70) and (B, 200) worms with normal sucker tegument (arrow) in (C,
Fig. 2. (A–H) Scanning electron microscopy of the tegument of the S. mansoni group treated with LPSF/PT-5 (A, 1000) where the appearance of bubbles (b) can be observed
at one hour of incubation with the second (B, 3350) also at the same time, showing peeling (p) and wrinkling of the tegument; (C, 200) at three hours of contact there is a
contraction in the sucker (arrow) of the parasite; (D, 1000) at three hours an increase in the number of bubbles between the tubercles (t); (E, 1000) and (F, 3350) at six
hours of contact, the outbreak of blisters can be seen; (G, 1000) and (H, 3350) at 12 h of incubation show an increase in shedding of the tegument at different resolutions.
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peeling of the worm tegument (Fig. 2A–H). After 1 h of incubation
with the compound LPSF/PT-11, we observed blisters and swellingof the tegument and loss of a few spines in the tubercules; after
3 h, increased swelling and loss of most spines spines and elonga-
tion of worm; after 6 h of contact we also noted greater elongation
Fig. 3. (A–H) Scanning electron microscopy of the tegument of the S. mansoni group treated with LPSF/PT-11 in (A, 1000) with a large number of bubbles (arrow) and
swelling of the coat at one hour of incubation with the compound; (B, 3350) also at the same time, with swelling and loss of spines of the trabeculae (arrow); (C, 3350) at
three contact hours, with swelling and barely visible thorns; (D, 70) at 3 h and (E, 50) at 6 h, there is an extension of the parasite; (F, 1000) at 6 hours of contact;
(G, 1000) and (H, 3350) at 12 hours of incubation showing changes to the tegument.
86 J.K.A.L. Neves et al. / Experimental Parasitology 128 (2011) 82–90of the worms when compared to LPSF/PT-5 and PZQ; after 12 h
there was peeling of the skin (Fig. 3A–H).Severe damage of the tegument was observed in male worms
after 1 h of incubation with PZQ at 80 lM concentration, such as
Fig. 4. (A–D) SEM of adult worms of S. mansoni after exposure to PZQ at 1,3,6 and 12 h, respectively. Observe the wrinkling (arrow), blisters (b) and peeling (p) (A, 3350);
contraction of the whole body (B–C, 70); moderate loss of spines, rupture of blisters and emergence of holes in the tegument (D, 3350).
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with PZQ, a contraction of the worm´s body was observed, which
was more evident after 6 h of treatment. After 12 h of exposure,
we observed in the worm tegument: rupture of blisters, the emer-
gence of several holes in the place where the blisters had been lo-
cated, and loss of spines (Fig. 4A–D).
3.2. PZQ cytotoxity was greater than that of the imidazolidine
derivatives and showed anti-S. mansoni activity
Beyond analyze anti-S. mansoni activity induced by imidazoli-
dines derivatives, we investigated the possible citotoxity activityTable 1
In vitro effects of LPSF/PT-05 and LPSF/PT-11 against Schistosoma mansoni adult worms an
Concentration (lM)
320 200 100 50 32
Time (h) Mortality (%) Observation (wo
LPSF/PT-05 24 100 100 100 21 2 Unpaired, no suc
tegument morph
48 100 100 100 64 10
72 100 100 100 64 12
96 100 100 100 71 25
120 100 100 100 100 25
LPSF/PT-11 24 100 100 100 39 11 Unpaired, no suc
appearance of b
48 100 100 100 56 16
72 100 100 100 85 84
96 100 100 100 100 89
120 100 100 100 100 100
Control group: paired adult worms without apparent morphological change, presence of
a Expressed as the highest concentration of imidozolidine tested that was not cytotox
b Calculated at ﬁve concentrations using data obtained from at least three independe
c Not determined.promoted by these new compounds against immune cells. For this,
we utilized the Tritiate Timidine ([3H]TdR) assay on splenocytes of
BALB/c mice. Praziquantel was used as the standard drug (positive
control) and cells without treatment as negative control. Results
showed that LPSF/PT-5 and LPSF/PT-11 presented nontoxic effects
at 5 and 1 lg mL1 concentrations (Table 1). On the other hand,
praziquantel showed higher toxicity in splenocytes at all tested
concentrations (Table 2). LPSF/PT-5 and LPSF/PT-11 were also
tested against S. mansoni adult worms and results were expressed
in terms of the IC50 (lM) values (Table 1). PZQ was also used as the
reference schistosomicide drug (Table 2). The two imidazolidine
derivatives induced 100% mortality of worms exposed to 100 lMd cytotoxic levels on mice splenocytes.
rms) Cytotoxicity (lg mL1)a IC50 (lM)b
ker adherence, absence of eggs
ology altered
5 57.79
47.44
48.59
47.37
39.75
ker adherence, absence of eggs,
ubbles, tegument morphology altered
5 51.33
49.58
52.11
NDc
ND
eggs.
ic to the BALB/c mice splenocytes.
nt experiments, with a SD less than 10% in all cases.
Table 2
In vitro effects of Praziquantel against Schistosoma mansoni adult worms and cytotoxic levels on mice splenocytes.
Concentration (lM)
80 40 20 10
Time (h) Mortality (%) Observation a(worms) Cytotoxicity a(lg mL1) IC50 (lM)b
PZQ 24 60 45 36 30 Fewer movements and contractions, absence of eggs, tegument morphology altered <1 37.02
48 66 56 50 45 35.08
72 76 67 57 53 33.91
96 100 100 100 92 15.36
120 100 100 100 92 15.36
a Control group: paired adult worms without apparent morphological change, presence of eggs.
b Expressed as the highest concentration of praziquantel tested that was not cytotoxic to the BALB/c mice splenocytes.
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exposure times (Table 1). Physiological alterations were induced
by all experimental drugs (imidazolidines and praziquantel) and
motor abnormalities of worms were similar between drugs (Tables
1 and 2). Oviposition by adult worms was also not observed at any
concentration of these imidazolidines and the control group (un-
treated worms) remained viable during the entire observation
times.
3.3. PZQ induced greater cell death than imidazolidines
To conﬁrm the ultrastructural results, some assays were per-
formed to evaluate the induction of cell death by imidazolidine
derivatives. These assays were done using BALB/c mice splenocytes
exposed to LPSF/PT-5, LPSF/PT-11 or PZQ at 1 lM concentration. To
measurements of cell damage, we investigated aspects of apoptosis
and necrosis in these treated splenocytes. Results showed that at
24 h, PZQ induced higher apoptosis in splenocytes compared to
LPSF/PT-5 and LPSF/PT-11 imidazolidines and LPSF/PT-11 wasFig. 5. Imidazolidine derivative effects on immune spleen cell viability. (A) Apoptosis inve
to PT-5 and PT-11 at 24 and 48 h. Only at 72 h did PT-5 induce higher apoptosis in relatio
assay using propidium iodide at 24, 48 and 72 h of assay. PZQ was superior to PT-5 and P
to control at 72 h of assay. PT-5 was only statistically superior to PT-11 at 24 h and PT-11
represent the average of three independent experiments per group. ⁄p < 0.05.superior to LPSF/PT-5 (Fig. 5A), but these drugs did not show statis-
tically signiﬁcant compared to the control (untreated cells). At the
same time, it was observed that LPSF/PT-5 was superior to LPSF/
PT-11 in terms of necrosis (Fig. 5B), but also not statistically signif-
icant compared to the control. PZQ induced more apoptosis than
LPSF/PT-5 and LPSF/PT-11 imidazolidines at 48 h of assay, but
not in relation to the control (Fig. 5A). However, PZQ induced high-
er and statistically signiﬁcant necrosis in splenocytes compared to
control, LPSF/PT-5 and LPSF/PT-11 imidazolidines. LPSF/PT-11 was
also greater than LPSF/PT-5 at this same time (Fig. 5B). At the last
time of assay, 72 h, LPSF/PT-5 and LPSF/PT-11 induced higher
apoptosis levels (Fig. 5A) and PZQ and LPSF/PT-11 induced higher
necrosis levels in relation to control cells (Fig. 5B).
4. Discussion
Schistosomiasis is a neglected disease that has one drug of
choice, praziquantel. Because of this, the Special Program for
Research and Training in Tropical Diseases promoted by WHOstigation utilizing annexin V at 24, 48 and 72 h of assay. PZQ was statistical superior
n to control and PT-11 was superior to PT-5 at 24 h and control at 72 h. (B) Necrosis
T-11 imidazolidines and in relation to control at 48 h of assay. PZQ was also superior
induced higher necrosis levels at 48 and 72 h in relation to control. Horizontal bars
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anti-parasitic drugs and encourages worldwide synthesis of new
compounds for these neglected diseases (Dias et al., 2009). Indeed,
many drugs have been compared with praziquantel and their cyto-
toxicity and ability to kill adult worms of S. mansoni have been
shown to be equivalent to praziquantel (Dayan, 2003; Sayed
et al., 2008). Here, LPSF/PT-5 and LPSF/PT-11 were less cytotoxic
and induced greater mortality of adult worms in relation to prazi-
quantel. But in relation to absence of oviposition by adult worms
and motor abnormalities, imidazolidines were similar to the refer-
ence drug. PZQ at low concentrations, in vitro, appears to impair
the function of the worms suckers and at higher concentrations in-
creases the contraction (irreversibly at very high concentrations) of
the worms’ strobilla (chain of proglottids) (Xiao et al., 1985; Cioli
and Pica-Mattoccia, 2003), causing irreversible focal vacuolization
with subsequent cestodal disintegration at speciﬁc sites of the
cestodal tegument (Martin, 1997; Badreldin, 2006). These same
physiological alterations were observed in adult worms treated
with imidazolidines here and in others studies realized by our
group (Albuquerque et al., 2005).
Currently, imidazolidines are being investigated for their anti-
parasite action. In schistosomiasis, imidazolidine composites have
shown action against adult worms (Pitta et al., 2006) and in anti-T.
cruzi assays these composites have been promising against epim-
astigotic forms (Caterina et al., 2008). However, similar to prazi-
quantel, the mechanism by which the imidazolidines exert
schistosomicide activity in vitro is still unclear. Many studies afﬁrm
that imidazolidines show activity in apoptotic cells with mela-
noma, their route was identiﬁed in S. mansoni (Dubois et al.,
2009) and possible activity at the cholinergic level receptors has
been suggested, since the nervous system of S. mansoni, with un-
ique pharmacological and physiological characteristics, can be
used in the research of compounds for human and animal use
(Thibaut et al., 2009).
The results of our ultrastructural analysis indicated that, like
praziquantel, imidazolidines induced serious damage to S. mansoni
tegument. Previous studies have also indicated that new com-
pounds have demonstrated anti-S. mansoni activity. Using arteme-
ther as a treatment against schistosimiasis Xiao et al. (2000)
showed contraction and swelling of the tegument with fusion of
the tubercles, blisters and a disorder in the arrangement of the
spines. Soliman and Ibrahim (2005) also demonstrated that
medroxyprogesterone acetate induced losing or shortening of
some tubercle spines, rupture of some tubercles, collapse of tissue
in the damaged area, mild to moderate erosion and peeling of the
tegument.
In addition, effects of artesunate were also described as severe
swelling, vacuolization and disruption, fusion of the tegumental
ridges, collapse and peeling. However, PZQ induced less severe
damage than artesunate (Jiraungkoorskul et al., 2005, 2006;
Shaohong et al., 2006).
Similarly, the results obtained in the present work, showed that
imidazolidine derivatives were more effective than PZQ in causing
tegumental damage in S. mansoni.
Many drugs have been shown to damage cell morphology in
in vitro assays and Annexin V appears to be a potent discriminator
between viable and apoptotic cells. Furthermore, propidium iodide
may be added to speciﬁcally stain the cells which have compro-
mised plasma membrane integrity (Vermes et al., 2000). Unlike
ultrastructural damage observed in S. mansoni tegument induced
by the imidazolidine derivatives LPSF/PT-5 and LPSF/PT-11, the cell
viability test demonstrated that new imidazolidine compounds
showed signiﬁcant splenocytes cell death only after 72 h of treat-
ment. Malheiros et al. (2000), using triﬂuoperazine (TFP), dibu-
caine (DBC) and praziquantel, observed cytotoxic effects such as
haemolysis and release of membrane lipids in human erythrocytemembranes, in a dose-dependent mechanism. Here, in the cell
death test, we observed that PZQ showed higher values at all
experimental times and some results were superior to imidazoli-
dines. But, the behavior by PT-11 was very similar to PZQ, indicat-
ing that it possibly activates similar routes in the induction of cell
death among the compounds evaluated and reference drug. How-
ever, more assays are needed to answer this question.
LPSF/PT-5 and LPSF/PT-11 imidazolidine derivatives showed
relevant schistosomicide activity in vitro and induced signiﬁcant
ultrastructural alterations in worms and cell death similarly to pra-
ziquantel. Thus, it is possible that these new imidazolidine deriva-
tives can be future candidates as schistosomotic drugs, but further
studies are needed to elucidate the mechanisms responsible for
this response.
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